Literature DB >> 24360397

Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

Liza C Villaruz1, Mark A Socinski2.   

Abstract

We report the identification of an FBXW7 mutation in a patient with adenocarcinoma of the lung, whose tumor had previously been shown to be EGFR and ALK wild type and who had previously progressed on multiple lines of systemic therapy. She experienced both clinical and radiographic benefit from treatment with the mTOR inhibitor temsirolimus.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  FBXW7 mutation; Lung adenocarcinoma; Next generation sequencing; Temsirolimus; mTOR inhibitor

Mesh：

Substances：

Year:  2013        PMID： 24360397      PMCID： PMC4836187          DOI： 10.1016/j.lungcan.2013.11.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  5 in total

1.  Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Suk Woo Nam; Won Sang Park; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

Review 2.  Personalized medicine in lung cancer: what we need to know.

Authors:  Tony S K Mok
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

3.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

4.  FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

Authors:  Jian-Hua Mao; Il-Jin Kim; Di Wu; Joan Climent; Hio Chung Kang; Reyno DelRosario; Allan Balmain
Journal:  Science       Date:  2008-09-12       Impact factor: 47.728

5.  FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Authors:  Shahab Akhoondi; Dahui Sun; Natalie von der Lehr; Sophia Apostolidou; Kathleen Klotz; Alena Maljukova; Diana Cepeda; Heidi Fiegl; Dimitra Dafou; Dimitra Dofou; Christian Marth; Elisabeth Mueller-Holzner; Martin Corcoran; Markus Dagnell; Sepideh Zabihi Nejad; Babak Noori Nayer; Mohammad Reza Zali; Johan Hansson; Susanne Egyhazi; Fredrik Petersson; Per Sangfelt; Hans Nordgren; Dan Grander; Steven I Reed; Martin Widschwendter; Olle Sangfelt; Charles Spruck
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701
  5 in total
  12 in total

1.  Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Authors:  Siraj M Ali; Sumanta K Pal; Kai Wang; Norma A Palma; Eric Sanford; Mark Bailey; Jie He; Julia A Elvin; Juliann Chmielecki; Rachel Squillace; Edward Dow; Deborah Morosini; Jamie Buell; Roman Yelensky; Doron Lipson; Garrett M Frampton; Peter Howley; Jeffrey S Ross; Philip J Stephens; Vincent A Miller
Journal:  Oncologist       Date:  2015-12-15

2.  TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.

Authors:  Anne M Schultheis; Luciano G Martelotto; Maria R De Filippo; Salvatore Piscuglio; Charlotte K Y Ng; Yaser R Hussein; Jorge S Reis-Filho; Robert A Soslow; Britta Weigelt
Journal:  Int J Gynecol Pathol       Date:  2016-07       Impact factor: 2.762

3.  FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.

Authors:  Hui Yang; Xiaofei Lu; Ziming Liu; Lili Chen; Yunfei Xu; Yuli Wang; Guangwei Wei; Yuxin Chen
Journal:  Oncotarget       Date:  2015-03-20

4.  Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Authors:  Maxim Ivanov; Konstantin Laktionov; Valery Breder; Polina Chernenko; Ekaterina Novikova; Ekaterina Telysheva; Sergey Musienko; Ancha Baranova; Vladislav Mileyko
Journal:  J Transl Med       Date:  2017-01-31       Impact factor: 5.531

5.  Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.

Authors:  Mashaal Dhir; Haroon A Choudry; Matthew P Holtzman; James F Pingpank; Steven A Ahrendt; Amer H Zureikat; Melissa E Hogg; David L Bartlett; Herbert J Zeh; Aatur D Singhi; Nathan Bahary
Journal:  Cancer Med       Date:  2016-12-28       Impact factor: 4.452

Review 6.  The importance of regulatory ubiquitination in cancer and metastasis.

Authors:  L H Gallo; J Ko; D J Donoghue
Journal:  Cell Cycle       Date:  2017-02-06       Impact factor: 4.534

7.  Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.

Authors:  Alice Guyard; Claire Danel; Nathalie Théou-Anton; Marie-Pierre Debray; Laure Gibault; Pierre Mordant; Yves Castier; Bruno Crestani; Gérard Zalcman; Hélène Blons; Aurélie Cazes
Journal:  Respir Res       Date:  2017-06-15

8.  Comparing two assays for clinical genomic profiling: the devil is in the data.

Authors:  Rachel M Squillace; Garrett M Frampton; Phil J Stephens; Jeffrey S Ross; Vincent A Miller
Journal:  Onco Targets Ther       Date:  2015-08-24       Impact factor: 4.147

Review 9.  Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.

Authors:  Jun Cao; Ming-Hua Ge; Zhi-Qiang Ling
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.

Authors:  Yi Xiao; Chunli Yin; Yuli Wang; Hanlin Lv; Wenqing Wang; Yurong Huang; Jesus Perez-Losada; Antoine M Snijders; Jian-Hua Mao; Pengju Zhang
Journal:  Mol Oncol       Date:  2018-05-09       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.